Abstract
Some women report cognitive impairment after adjuvant chemotherapy (CTh) for breast cancer. Here we explore cognitive function, and underlying mechanisms with blood tests and functional magnetic resonance imaging (fMRI). Women treated for early breast cancer were recruited to three groups based on self-reported cognitive symptoms (CS) using FACT-Cog scores. CTh + CS+ (n = 44) had received chemotherapy and self-reported cognitive symptoms; CTh + CS- (n = 52) had chemotherapy but did not report cognitive problems; CTh- (n = 30) had not received chemotherapy. Clinical and computer-based neuropsychological tests were performed. Blood tests included 10 cytokines, sex hormones, coagulation factors, and apolipoprotein-E genotype. fMRI (n = 101) was performed while subjects performed an n-back memory task. Participants had median age 50 (range: 29–60) years and were a median of 17 months post-diagnosis. On clinical neuropsychological tests 19% had cognitive impairment using Global Deficit Score, and 36% using International Cancer and Cognition Task Force criteria with no significant differences in cognitive impairment rates between groups. CTh + CS+ had significantly more fatigue, anxiety/depression and poorer quality-of-life than other groups. There was no association between FACT-Cog and neuropsychological scores. There were significant differences in frontal and parietal regions on fMRI scans: CTh- showed hyperactivation compared to chemotherapy-treated groups, CTh + CS+ had more frontal activation than CTh + CS-. Elevated IL-1, IL-2 were associated weakly and IL-8 more strongly with neuropsychological impairment (rho > 0.20). There were no differences in global cognitive impairment between groups. Cognitive symptoms were associated with fatigue and anxiety/depression, but not with objective cognitive impairment. fMRI scans differed among the three groups.
Similar content being viewed by others
References
Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews. Cancer, 7(3), 192–201.
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20(2), 485–493.
Ahles, T. A., Saykin, A. J., Noll, W. W., Furstenberg, C. T., Guerin, S., Cole, B., & Mott, L. A. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology, 12(6), 612–619.
Bower, J. E., Ganz, P. A., Desmond, K. A., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743–753.
Burgess, P. W., Alderman, N., Evans, J., Emslie, H., & Wilson, B. A. (1998). The ecological validity of tests of executive function. Journal of the International Neuropsychological Society, 4(6), 547–558.
Carey, C. L., Woods, S. P., Gonzalez, R., Conover, E., Marcotte, T. D., Grant, I., & Heaton, R. K. (2004). Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. Journal of Clinical and Experimental Neuropsychology, 26(3), 307–319.
Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26(7), 955–969.
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., . . . et al. (1993). The functional Assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.
Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94(2), 528–538.
Chelune, G., Heaton, RK., Lehman, RAW., et al. (1986). Neuropscychological and personality correlates of patients' complaints of disability. In G. Goldstein, tarter, RE., (Ed.), Advances in Clinical Neuropsychology (Vol. 3, pp. 95-126). New York: Plenum press.
Conroy, S. K., McDonald, B. C., Smith, D. J., Moser, L. R., West, J. D., Kamendulis, L. M., et al. (2013). Alterations in brain structure and function in breast cancer survivors: Effect of post-chemotherapy interval and relation to oxidative DNA damage. [research support, N.I.H., extramural, research support, non-U.S. Gov't]. Breast Cancer Research and Treatment, 137(2), 493–502. doi:10.1007/s10549-012-2385-x.
Fitzgerald, P. B., Laird, A. R., Maller, J., & Daskalakis, Z. J. (2008). A meta-analytic study of changes in brain activation in depression. [meta-analysis research support, N.I.H., extramural, research support, non-U.S. Gov't]. Human Brain Mapping, 29(6), 683–695. doi:10.1002/hbm.20426.
Ganz, P. A., Bower, J. E., Kwan, L., Castellon, S. A., Silverman, D. H., Geist, C., . . . Cole, S. W. (2013). Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? [research support, N.I.H., extramural, research support, non-U.S. Gov't]. Brain Behav Immun, 30 Suppl, S99-108. doi:10.1016/j.bbi.2012.07.015.
Goldberg, D. P. (1991). A user's guide to the general health questionnaire: NFER-Nelson.
Gotlib, I. H., Sivers, H., Gabrieli, J. D., Whitfield-Gabrieli, S., Goldin, P., Minor, K. L., & Canli, T. (2005). Subgenual anterior cingulate activation to valenced emotional stimuli in major drepression. [comparative study, research support, N.I.H., extramural]. Neuroreport, 16(16), 1731–1734.
Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., et al. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109(1), 146–156.
Ingraham, L., & Aiken, C. B. (1996). An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology, 10(1), 120–124.
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., et al. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94(6), 828–834.
Kesler, S. R., Kent, J. S., & O'Hara, R. (2011). Prefrontal cortex and executive function impairments in primary breast cancer. [comparative study, research support, N.I.H., extramural]. Archives of Neurology, 68(11), 1447–1453. doi:10.1001/archneurol.2011.245.
Kesler, S., Janelsins, M., Koovakkattu, D., Palesh, O., Mustian, K., Morrow, G., & Dhabhar, F. S. (2013). Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. [research support, N.I.H., extramural, research support, non-U.S. Gov't]. Brain, Behavior, and Immunity, 30 Suppl, S109-116. doi:10.1016/j.bbi.2012.05.017.
Koppelmans, V., de Groot, M., de Ruiter, M. B., Boogerd, W., Seynaeve, C., Vernooij, M. W., et al. (2014). Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Human Brain Mapping, 35(3), 889–899. doi:10.1002/hbm.22221.
McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D., & Saykin, A. J. (2012). Alterations in brain activation during working memory processing associated with breast cancer and treatment: A prospective functional magnetic resonance imaging study. [research support, N.I.H., extramural, research support, non-U.S. Gov't]. Journal of Clinical Oncology, 30(20), 2500–2508. doi:10.1200/JCO.2011.38.5674.
McDonald, B. C., Conroy, S. K., Smith, D. J., West, J. D., & Saykin, A. J. (2013). Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study. [research support, N.I.H., extramural, research support, non-U.S. Gov't]. Brain, Behavior, and Immunity, 30 Suppl, S117-125. doi:10.1016/j.bbi.2012.05.007.
Menning, S., de Ruiter, M. B., Veltman, D. J., Koppelmans, V., Kirschbaum, C., Boogerd, W., et al. (2015). Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment--the role of fatigue. [research support, non-U.S. Gov't]. Neuroimage Clin, 7, 547–554. doi:10.1016/j.nicl.2015.02.005.
Pannekoek, J. N., van der Werff, S. J., van Tol, M. J., Veltman, D. J., Aleman, A., Zitman, F. G., et al. (2015). Investigating distinct and common abnormalities of resting-state functional connectivity in depression, anxiety, and their comorbid states. European Neuropsychopharmacology, 25(11), 1933–1942. doi:10.1016/j.euroneuro.2015.08.002.
Patel, S. K., Wong, A. L., Wong, F. L., Breen, E. C., Hurria, A., Smith, M., . . . Bhatia, S. (2015). Inflammatory biomarkers, comorbidity, and Neurocognition in women with newly diagnosed breast cancer. [comparative study research support, N.I.H., extramural, research support, non-U.S. Gov't]. J Natl Cancer Inst, 107(8). doi:10.1093/jnci/djv131.
Piccirillo, J. F., Hardin, F. M., Nicklaus, J., Kallogjeri, D., Wilson, M., Ma, C. X., et al. (2015). Cognitive impairment after chemotherapy related to atypical network architecture for executive control. [clinical trial research support, N.I.H., extramural, research support, non-U.S. Gov't]. Oncology, 88(6), 360–368. doi:10.1159/000370117.
de Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., van Dam, F. S., Nederveen, A. J., et al. (2011). Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping, 32(8), 1206–1219. doi:10.1002/hbm.21102.
de Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., Caan, M., Douaud, G., et al. (2012). Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. [research support, non-U.S. Gov't]. Human Brain Mapping, 33(12), 2971–2983. doi:10.1002/hbm.21422.
Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85(3), 640–650.
Schagen, S. B., Muller, M. J., Boogerd, W., Mellenbergh, G. J., & van Dam, F. S. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98(23), 1742–1745.
Schlund, M. W., Verduzco, G., Cataldo, M. F., & Hoehn-Saric, R. (2012). Generalized anxiety modulates frontal and limbic activation in major depression. [research support, non-U.S. Gov't]. Behav Brain Funct, 8, 8. doi:10.1186/1744-9081-8-8.
Servaes, P., Gielissen, M. F., Verhagen, S., & Bleijenberg, G. (2007). The course of severe fatigue in disease-free breast cancer patients: A longitudinal study. Psychooncology, 16(9), 787–795. doi:10.1002/pon.1120.
Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21(22), 4175–4183.
Vardy, J., Wong, K., Yi, Q. L., Park, A., Maruff, P., Wagner, L., & Tannock, I. F. (2006). Assessing cognitive function in cancer patients. Support Care Cancer, 14(11), 1111–1118.
Vardy, J. L., Booth, C., Pond, G. R., Zhang, H., Galica, J., Dhillon, H., . . . Tannock, I. F. (2007). Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. ASCO Meeting Abstracts, 25(18_suppl), 9070-.
Vardy, J., Dhillon, H. M., Pond, G. R., Rourke, S. B., Xu, W., Dodd, A., et al. (2014). Cognitive function and fatigue after diagnosis of colorectal cancer. Annals of Oncology, 25(12), 2404–2412. doi:10.1093/annonc/mdu448.
Vardy, J. L., Dhillon, H. M., Pond, G. R., Rourke, S. B., Bekele, T., Renton, C., et al. (2015). Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: A prospective, longitudinal, controlled study. [comparative study research support, N.I.H., extramural, research support, non-U.S. Gov't]. Journal of Clinical Oncology, 33(34), 4085–4092. doi:10.1200/JCO.2015.63.0905.
Wagner, L., Sweet, J., Butt, Z., Lai, J., & Cella, D. (2009). Measuring patient self-reported cognitive function: Development of the functional Assessment of cancer therapy - Cognitive function instrument. The Journal of Supportive Oncology, 7(6), W32–W39.
Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010). Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 116, 3348–3356. doi:10.1002/cncr.25098.
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International Cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncology, 12(7), 703–708. doi:10.1016/S1470-2045(10)70294-1.
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the functional Assessment of cancer therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63–74.
Acknowledgements
This study was supported by a developmental grant from the Canadian Breast Cancer Research Alliance, and expanded with support from the Susan G. Komen Breast Cancer Foundation. Dr. Janette Vardy is supported by a Practitioner Fellowship from the National Breast Cancer Foundation, Australia.
We thank Irene Chemerysnky and Alison Park for performing the neuropsychological testing, David Laurence and Jessica Zhang for data management, Hien Tran for assistance with MRI testing, and Drs Michiel de Ruiter, Taylor Schmitz and Kimberley Chiew for initial advice and assistance with fMRI imaging processing. We thank all the patients who participated in the study and acknowledge the assistance of the clinicians and clinical trial nurses.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by a developmental grant from the Canadian Breast Cancer Research Alliance, and expanded with support from the Susan G. Komen Breast Cancer Foundation. Dr. Janette Vardy is supported by a Practitioner Fellowship from the National Breast Cancer Foundation, Australia.
Conflicts of interest
None of the authors have any conflicts of interest to report.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Institute where work performed: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Electronic supplementary material
ESM 1
(DOCX 116 kb)
Rights and permissions
About this article
Cite this article
Vardy, J.L., Stouten-Kemperman, M.M., Pond, G. et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging and Behavior 13, 15–26 (2019). https://doi.org/10.1007/s11682-017-9728-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11682-017-9728-5